<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517175</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1345</org_study_id>
    <nct_id>NCT04517175</nct_id>
  </id_info>
  <brief_title>Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?</brief_title>
  <official_title>Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zuyderland Medisch Centrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ki-67 is used as a marker for determination of the proliferative activity in solid tumors.&#xD;
      The use within hemato-oncological malignancies is limited. This is related to limited&#xD;
      technical possibilities of flow cytometry in the past. Meanwhile, flow cytometry in&#xD;
      hemato-oncological malignancies has progressed to assessment of 8 colors and makes it&#xD;
      possible to add Ki-67 as an additional marker to the 8-color panels. Adding Ki-67 to these&#xD;
      panels could lead to improved diagnosis and prediction of therapy response for a number of&#xD;
      hemato-oncological malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maturation patterns diagnosis</measure>
    <time_frame>5 years</time_frame>
    <description>Maturation patterns based on immunophenotype for red blood cells and several types of immune cells and their respective contributions to diagnosis.&#xD;
Maturation patterns are scored by various methods/combinations to form diagnostic score. A higher diagnostic score will lead to a more likely diagnose for MDS and/or AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proliferative index diagnosis</measure>
    <time_frame>5 years</time_frame>
    <description>Ki-67 proliferative index (within populations and maturation) and its contribution to diagnosis. A lower Ki-67 proliferative index will lead to a more likely diagnose for MDS and/or AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proliferative index prognosis</measure>
    <time_frame>5 years</time_frame>
    <description>Ki-67 as prognostic parameter. A lower Ki-67 proliferative index will (hypothetically) lead to worse prognosis for MDS and AML in terms of: transfusion dependence (expressed in amount of transfusions in 2 months), chemotherapy response (expressed as total remission, normalization of blood values, possibly also normalization of cytogenetics in bone marrow cells), overall survival (expressed in months after diagnosis), Risk scores. Higher risk scores are correlated with worse prognosis.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome/Neoplasm</condition>
  <arm_group>
    <arm_group_label>Myelodysplastic syndrome (MDS) patients</arm_group_label>
    <description>MDS patients will be divided according to prognostic parameters in sub-cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute myeloid Leukemia (AML) patients</arm_group_label>
    <description>AML patients will be divided according to prognostic parameters in sub-cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myelodysplastic syndrome/neoplasm (MDS/MPN) patients</arm_group_label>
    <description>MDS/MPN patients will be divided according to prognostic parameters in sub-cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow cytometry</intervention_name>
    <description>Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.</description>
    <arm_group_label>Acute myeloid Leukemia (AML) patients</arm_group_label>
    <arm_group_label>Myelodysplastic syndrome (MDS) patients</arm_group_label>
    <arm_group_label>Myelodysplastic syndrome/neoplasm (MDS/MPN) patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in which a hemato-oncological malignancy is found and are at least 18 years old.&#xD;
        These patients can be male and female.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MDS and AML patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing radio- and/or chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathie Leers, Dr.</last_name>
    <phone>+31 45 5767503</phone>
    <email>mat.leers@zuyderland.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bart de Wit, Dr.</last_name>
    <phone>+31 43 3874694</phone>
    <email>b.de.wit@mumc.nl</email>
  </overall_contact_backup>
  <reference>
    <citation>Nies KPH, Kraaijvanger R, Lindelauf KHK, Drent RJMR, Rutten RMJ, Ramaekers FCS, Leers MPG. Determination of the proliferative fractions in differentiating hematopoietic cell lineages of normal bone marrow. Cytometry A. 2018 Nov;93(11):1097-1105. doi: 10.1002/cyto.a.23564. Epub 2018 Sep 3.</citation>
    <PMID>30176186</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University</investigator_affiliation>
    <investigator_full_name>Stefan Mestrum</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ki-67</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

